Actively Recruiting
Randomized Double-Blind Study Evaluating DDY391 for Moderate to Severe Psoriatic Arthritis with Dose-Response Assessment
Led by Novartis Pharmaceuticals · Updated on 2026-10-13
220
Participants Needed
3
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the drug DDY391 in adults with moderate to severe psoriatic arthritis PsA in this Phase 2ab clinical trial. The study aims to assess the effectiveness, safety, and how well patients tolerate DDY391. It also seeks to understand how different doses of DDY391 affect patients to help select the best dose for future studies. This randomized, double-blind, placebo-controlled trial has two parts Part A compares DDY391 to a placebo to evaluate its effects and safety, while Part B explores the dose-response relationship by testing multiple doses of DDY391 against placebo. Participants receive different schedules and doses of DDY391 or matching placebo, with some switching to standard care depending on their response. Participants will undergo regular assessments to measure their arthritis symptoms using the American College of Rheumatology 50 ACR50 response at 12 weeks. Safety is monitored by tracking adverse events throughout the study. The trial involves multiple visits for treatment administration and evaluations, with the primary outcome focused on improvement in PsA symptoms after 12 weeks of treatment.
CONDITIONS
Brief Title
A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here